Congress Presentation presented at AHA 2017 given by Dr. Chris Cannon with slides on a neutral background ( only Study branding) Including Q&A with Dr. Cannon and Dr. Hohnloser on FAQs related to the study results as well as the clinical implications of the results.
Q&A 1: What may be the implication of the RE-DUAL PCI study results for clinical practice?
Q&A 2: Why are alternative treatment options needed for prevention of thrombosis in patients undergoing PCI?
Q&A 3: What is the objective and design of the RE-DUAL PCI study?
Q&A 4: Why was aspirin only given for 1 or 3 months?
FAQs related to the study results as well as the clinical implications of the results.